Alkermes plc.
ALKS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001520262
In the last 90 days, Alkermes plc. insiders filed 0 open-market purchases and 8 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $9.32B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alkermes plc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 4 insiders, $4.24M in total
- Insiders trading
- 4
- Net value
- −$4.24M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alkermes plc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | 223,422 | Sep 3, 2026 | 11 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | 65,389 | Sep 1, 2026 | 18 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | 102,193 | Aug 17, 2026 | 6 |
| Jackson Blair Curtis | President & CEO, Alkermes plc | 241,308 | Aug 7, 2026 | 6 |
| snyderman nancy lynn MD | Director | 15,395 | Aug 3, 2026 | 2 |
| Wright Christopher I | Director | 25,680 | Jun 12, 2026 | 2 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | 7,717 | May 29, 2026 | 5 |
| McKeon Brian P | Director | 38,536 | May 22, 2026 | 1 |
| Laurencin Cato T | Director | 33,769 | May 22, 2026 | 1 |
| Lurker Nancy | Director | 18,222 | May 22, 2026 | 2 |
| Wilson Frank Anders | Director | 35,751 | May 22, 2026 | 1 |
| Cooke Shane | Director | 106,679 | May 22, 2026 | 2 |
| Gaynor Richard | Director | 35,751 | May 22, 2026 | 1 |
| Pops Richard F | Director and CEO, Alkermes plc | 1,377,740 | Mar 4, 2026 | 2 |
| Reed Joshua | SVP, Chief Financial Officer | – | Mar 4, 2026 | 2 |
| Brown Iain Michael | SVP, Chief Financial Officer | 148,196 | Feb 28, 2025 | 0 |
| Alva Emily Peterson | Director | 27,302 | Jul 1, 2024 | 0 |
| Daglio David Angelo Jr. | Director | 27,780 | Jul 1, 2024 | 0 |
| Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | 281,730 | Feb 27, 2024 | 0 |
| Wysenski Nancy | Director | 20,356 | Jul 10, 2023 | 0 |
| Anstice David W | Director | 84,905 | Jun 16, 2022 | 0 |
| Dixon Wendy L | Director | 53,124 | Jun 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Nichols Christian ToddSVP, Chief Commercial Officer | SSale | −6.00K | $30.00 | −$180.0K | −5.2%109.8K after | 10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Parisi Samuel JosephVP, Finance (Interim PAO) | SSale | −6.89K | $29.29 | −$201.8K | −47.2%7.72K after | 10b5-1 |
| Apr 1, 2026 (view filing) | Apr 1 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $35.51 | −$319.6K | −9.5%85.4K after | 10b5-1 |
| Apr 6, 2026 (view filing) | Apr 6 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $34.57 | −$70.3K | −0.9%233.6K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $33.40 | −$300.6K | −10.0%81.4K after | 10b5-1 |
| May 4, 2026 (view filing) | May 4 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $33.20 | −$67.5K | −0.9%231.6K after | 10b5-1 |
| May 29, 2026 (view filing) | May 29 | Same day | Parisi Samuel JosephVP, Finance (Interim PAO) | SSale | −16.2K | $42.36 | −$687.0K | −67.8%7.72K after | |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $41.67 | −$375.0K | −10.4%77.4K after | 10b5-1 |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $43.05 | −$87.6K | −0.9%229.5K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 12 | Same day | Wright Christopher IDirector | SSale | −2.00K | $45.10 | −$90.2K | −7.2%25.7K after | 10b5-1 |
| Jul 1, 2026 (view filing)6:29 PM ET | Jul 1 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $51.51 | −$463.6K | −10.9%73.4K after | 2 lots10b5-1 |
| Jul 6, 2026 (view filing)4:48 PM ET | Jul 6 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $54.03 | −$109.9K | −0.9%227.5K after | 10b5-1 |
| Aug 3, 2026 (view filing)7:09 PM ET | Aug 3 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $48.58 | −$98.8K | −0.9%225.5K after | 10b5-1 |
| Aug 3, 2026 (view filing)7:12 PM ET | Aug 3 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $48.58 | −$437.2K | −11.5%69.4K after | 10b5-1 |
| Aug 3, 2026 (view filing)7:16 PM ET | Aug 3 | Same day | snyderman nancy lynn MDDirector | SSale | −44.5K | $50.35 | −$2.24M | −74.3%15.4K after | |
| Aug 17, 2026 (view filing)6:53 PM ET | Aug 17 | Same day | Nichols Christian ToddSVP, Chief Commercial Officer | SSale | −7.58K | $49.23 | −$372.9K | −6.9%102.2K after | 2 lots10b5-1 |
| Sep 1, 2026 (view filing)7:08 PM ET | Sep 1 | Same day | Hopkinson Craig C.EVP R&D, Chief Medical Officer | SSale | −9.00K | $46.99 | −$422.9K | −12.1%65.4K after | 10b5-1 |
| Sep 3, 2026 (view filing)6:32 PM ET | Sep 3 | Same day | Gaffin David JosephEVP, CLO, Alkermes, Inc. | SSale | −2.03K | $48.01 | −$97.7K | −0.9%223.4K after | 10b5-1 |